Celltrion, Inc.
Biopharmaceutical firm developing biosimilars for autoimmune diseases and oncology.
068270 | KO
Overview
Corporate Details
- ISIN(s):
- KR7068270008
- LEI:
- Country:
- South Korea
- Address:
- 인천광역시 연수구 아카데미로 23, 인천광역시
- Website:
- https://www.celltrion.com/
- Sector:
- Manufacturing
Description
Celltrion, Inc. is a biopharmaceutical company that provides integrated solutions across the entire value chain, from research and development to clinical trials, regulatory affairs, and large-scale manufacturing. The company specializes in developing and producing innovative therapeutics, including biosimilars and novel biopharmaceuticals. Its portfolio primarily targets autoimmune diseases and oncology. Celltrion is recognized for launching the world's first monoclonal antibody biosimilar. A key product is ZYMFENTRA® (infliximab-dyyb), a subcutaneous formulation for the maintenance treatment of moderately-to-severely active Crohn's disease and ulcerative colitis. The company also develops and manufactures chemical pharmaceuticals.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-06-24 00:00 |
투자판단관련주요경영사항 (옴리클로CT-P39, 졸레어 바이오시밀러 한국MFDS 품목허가 획득)
|
Korean | 7.9 KB | ||
| 2024-06-21 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 21.7 KB | ||
| 2024-06-19 00:00 |
투자판단관련주요경영사항 (CT-P13 SC짐펜트라 미국 임상 3상 시험계획 신청 류마티스 관절염 환자)
|
Korean | 10.0 KB | ||
| 2024-06-18 00:00 |
투자판단관련주요경영사항 (CT-P13 SC램시마 피하주사 제형 유럽 임상 3상 시험계획 승인Part 1 궤양성 대장염 …
|
Korean | 11.8 KB | ||
| 2024-06-18 00:00 |
투자판단관련주요경영사항 (CT-P13 SC램시마 피하주사 제형 유럽 임상 3상 시험계획 승인Part 1 크론병 소아 환…
|
Korean | 11.8 KB | ||
| 2024-06-17 00:00 |
투자판단관련주요경영사항 (CT-P51키트루다 바이오시밀러 미국 임상 3상 시험계획 신청)
|
Korean | 9.8 KB | ||
| 2024-06-14 00:00 |
주요사항보고서(자기주식취득결정)
|
Korean | 28.8 KB | ||
| 2024-06-14 00:00 |
주식등의대량보유상황보고서(일반)
|
Korean | 636.4 KB | ||
| 2024-06-12 00:00 |
투자판단관련주요경영사항 (스테키마CT-P43, 스텔라라 바이오시밀러 한국MFDS 품목허가 획득)
|
Korean | 8.5 KB | ||
| 2024-06-04 00:00 |
자기주식취득결과보고서
|
Korean | 38.1 KB | ||
| 2024-05-31 00:00 |
대규모기업집단현황공시[연1회공시및1/4분기용(개별회사)]
|
Korean | 225.3 KB | ||
| 2024-05-31 00:00 |
기업지배구조보고서공시
|
Korean | 1.1 MB | ||
| 2024-05-30 00:00 |
투자판단관련주요경영사항 (아이덴젤트CT-P42, 아일리아 바이오시밀러 한국MFDS 품목허가 획득)
|
Korean | 8.6 KB | ||
| 2024-05-24 00:00 |
투자판단관련주요경영사항 (옴리클로(CT-P39, 졸레어 바이오시밀러) 유럽연합진행위원회(EC) 최종판매허가 획득)
|
Korean | 9.5 KB | ||
| 2024-05-24 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 20.9 KB |
Automate Your Workflow. Get a real-time feed of all Celltrion, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Celltrion, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Celltrion, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
